Smokeless Cannabis: Products, Effects and Risks

Smokeless cannabis includes products that are inhaled, swallowed or applied to the skin. Those routes have different characteristics. Choosing a product that does not burn does not remove every health risk or establish that it will treat a particular condition.

Vaporized cannabis still involves inhalation

Dry herb vaporizers heat flower, while cartridges and concentrate devices use other preparations. Findings about one device should not be assumed to apply to every vape. The CDC notes that oils and concentrates may contain high THC levels, additives or contaminants, and that vaping has been linked to lung injury. Read the CDC’s cannabis risk guidance.

Vapor should not be described as toxin-free. For more on the difference between device measurements and health outcomes, see our guide to cannabis vaporization research.

Edibles and capsules can have delayed effects

Swallowed products avoid inhaling smoke, but their effects can take longer to appear. Health Canada explains that edible effects may begin after 30 minutes to two hours, with full effects taking up to four hours. Taking more before the first amount has fully taken effect increases the risk of adverse effects. These are general ranges, not a guarantee for an individual. Read Health Canada’s consumer guidance.

For a medical treatment plan, discuss the exact product and its timing with your clinician. A delayed onset should not be interpreted as proof that the product is inactive.

Prescription cannabinoid medicines are a separate category

Evidence for an approved prescription medicine should not be applied to every edible or oil. The FDA distinguishes approved cannabinoid medicines, including certain products used for chemotherapy-related nausea, from unapproved cannabis products. A similar ingredient does not establish equivalent effectiveness, quality or safety. See the FDA’s explanation of cannabis drug approval.

Topicals and transdermal products need product-specific evidence

A product applied to the skin and one designed for delivery through the skin are not automatically interchangeable. The formulation and the evidence supporting its intended use matter.

The arthritis study cited in the original version of this guide tested transdermal CBD in rats. Its findings about inflammation and pain-related behavior do not establish that a retail balm treats rheumatoid arthritis in people. Read the Hammell and colleagues study.

Our topical and transdermal cannabinoids guide explains those evidence limits in more detail. Do not replace prescribed arthritis care based on an animal study or a product testimonial.

How to compare options with your clinician

• Your goal: identify the symptom you want to address and how you will judge improvement.
• The specific product: bring its label and ingredients rather than relying only on a category such as oil or full-spectrum.
• Your current care: review medications, health history and previous adverse reactions.
• Follow-up: agree when to review benefit, unwanted effects and whether the plan should change.

THC can impair attention and decision-making regardless of how it is used, and cannabis can interact with medicines. The CDC does not identify one consumption method as universally safest. See its comparison of cannabis routes and risks.

This guide provides general education. A qualified clinician can help assess options in the context of your own medical care.